INTRODUCTION
Immunotherapy holds great potential for the treatment and management of cancer patients with advanced disease (1) . Through numerous divergent mechanisms, including monocyte maturation in the presence of tumor antigens (2) and the genetic engineering of immune cells (3) , the body's adaptive immune system can be primed to target malignancies normally recognized as "self." Although the success of recent phase 3 trials has validated the principle that immunotherapy can sometimes extend cancer patient survival (4), tumor cells can escape immune surveillance and develop resistance to immunotherapy (5) . Examples of resistance mechanisms include the regulation of immune checkpoints (6) , resistance to cell death signaling (7) , or regulation by other tumor-associated immune cells, such as regulatory T cell lymphocytes (8) . Given the variable success of immunotherapy in the clinic (9) (10) (11) , there is an urgent need to design noninvasive techniques that could give early indications of response to treatment and help predict patient outcome.
Current methods used for the assessment of tumor response to therapy primarily rely on measurements of tumor size through anatomical imaging using the response evaluation criteria in solid tumors (RECIST) (12) . The limitations of anatomical imaging for response monitoring in solid tumors have been well documented (13) . Assessment of immunotherapy efficacy provides particular challenges in that the influx of effector cells to the tumor microenvironment may result in "pseudoprogression" as defined by RECIST, which is not linked to long-term outcome (14) . These limitations have led to the development of a specific set of immunerelated response criteria (irRC) (14, 15) . However, irRC measurements provide no biological information and can take 8 to 12 weeks for an initial response assessment, by which time nonresponding patients may have missed their therapeutic window and experienced unnecessary therapy-related toxicity. In addition, adaptive immune responses involving T and B lymphocytes, which have demonstrated great therapeutic potential, require monitoring of immune cell trafficking to the tumor site, lymphocyte retention, and immune cell engagement with the tumor cells. At present, techniques to noninvasively assess the in vivo viability and trafficking of these immune cells in cancer patients are not available.
We previously provided a demonstration of imaging cells in a single case report using reporter gene technology (16) . In that case study, therapeutic T cells expressing a positron emission tomography (PET) reporter gene were injected into the tumor resection site of a 57-year-old male high-grade glioma patient and then visualized by molecular imaging with a PET reporter probe (16) . For that study, we used genetically modified CD8 + autologous cytotoxic T lymphocytes (CTLs) stably expressing the chimeric antigen receptor (CAR) interleukin-13 (IL-13) zetakine for IL-13Ra2 + tumor targeting (17) (18) (19) and the herpes simplex virus type 1 thymidine kinase gene (HSV1-tk) as a dual-purpose suicide (20, 21) and imaging reporter gene ( Fig. 1) (22, 23) . HSV1-tk was fused in-frame with the hygromycin phosphotransferase (hph) gene and expressed as a fusion protein. HPH expression conferred hygromycin B resistance for dominant positive selection. Through imaging of HSV1-tk reporter gene expression using 9-[4-[ , which is a fluorine-18 radiolabeled analog of the antiherpes drug penciclovir (Fig. 1, inset) , we could image [ 18 F]FHBG trapping in the brain tumor, which was thought to correspond to CTL accumulation. This corroborated the extensive preclinical assessment of this targeted strategy (24) . However, this study in a single patient was limited because, at that time, we only had U.S. Food and Drug Administration (FDA) approval to perform one PET scan after the infusion of CTLs and did not have a critical baseline PET image before CTL injection. Therefore, we could not confirm that the brain-associated [ 18 F]FHBG signal was CTL-specific (22) .
Expanding on this pilot case study, we sought to assess the ability of [ 18 F]FHBG to longitudinally monitor CTL trafficking, survival, and proliferation in multiple patients with recurrent high-grade gliomas that were resistant to conventional therapies. Under this protocol, seven patients received several infusions of either autologous or allogeneic engineered CTLs (Fig. 1) . CTL location and response were noninvasively measured by PET using a strategy outlined in Fig. 2 . In addition, we evaluated the safety of the CTLs injected into the central nervous system and the safety of recombinant human IL-2 delivery in conjunction with CTL adoptive cell transfer, a strategy used to prolong the survival of engineered CTLs and potentially improve their therapeutic efficacy.
RESULTS

Patient enrollment and CTL characterization
To conduct a detailed evaluation of the use of [ 18 F]FHBG to track genetically engineered CTLs for immunotherapy, we enrolled a total of four men and three women (average age of 57 ± 8 years old with recurrent high-grade glioma) under two separate Institutional Review Board (IRB)-approved protocols (Table 1) . Patient 1 in this study is the patient from our previous case report (16) . Autologous (NCT00730613) (17) and allogeneic (NCT01082926) CTLs for immunotherapy were engineered to express the tumor-targeting IL-13 zetakine CAR and the wild-type HSV1-tk gene reporter. This CAR recognizes IL-13Ra2, a cell surface receptor expressed in more than 50% of glioblastoma cells but not in normal brain tissue (25, 26) . The CTLs were >99% CD8. We first confirmed our previous finding (27, 28) (29) . Here, we observed similar radiotracer biodistribution ( fig. S3 ), as assessed by standardized uptake value (SUV) mean measurements on the pre-and post-CTL injection scans using a 50-mm-diameter spherical volume of interest (VOI). In pre-CTL treatment scans, at a mean time of 137 ± 11 min after injection of [ F]FHBG retention in both gliomas and previous surgical sites before CTL infusion, it was essential to perform baseline and follow-up scans in the same patients after CTL injection (16) . A total of 10 tumor foci were analyzed in the seven patients, with two sites each assessed for patients 1, 4, and 7. We did not obtain a pre-CTL [ (Fig. 3, A and B, and movie S1). The HSV1-tk complex is a genetically modified structure that was transfected into either autologous or allogeneic CTLs. This complex expresses a fusion protein consisting of a selective gene (hygromycin resistance locus) for adequate in vitro expansion of the CTL line; a PET reporter gene and safety gene, HSV1-tk; a glucocorticoid receptor (GR) resistance locus for improving CTL survival despite the high doses of steroids routinely given to highgrade glioma patients; and an IL-13 zetakine domain, which is a chimeric receptor that enables glioma cell recognition by CTLs. CTL transfection was performed by electroporation. Inside the transfected cells, HSV1-tk is transcribed and translated to produce the HSV1-TK enzyme. [ S4 ). After intracerebral injection, there is the potential for CTLs to diffuse in the surgical cavity or the brain parenchyma. To optimize the monitoring of CTL trafficking to targeted areas, better imaging metrics were needed to replace single-voxel measurements such as SUV max , particularly when the localization of CTLs, and therefore the VOI, was unknown. The first challenge was to define an accurate VOI. Given the availability of contrast-enhanced MR images taken from the same patients before and after CTL infusions, it was possible to derive VOIs from enhancing regions of the tumor. MRI-based [ Analysis of the total activity in patients for whom the size of the VOI did not change, such as patient 6, clearly indicated a shift in SUV histograms after CTL infusions (Fig. 3C ), corresponding to a doubling of [ 18 F]FHBG uptake at the site were expected between scans. In the post-CTL scan, however, a 66% increase in [ 18 F]FHBG total activity was measured by comparison to the baseline scan, from 1.6 to 2.7, which was further supported by minimal changes in the dispersion of voxel intensities (Fig. 4F ). This is in Noninjected foci total activity pre-CTL
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Noninjected foci total activity post-CTL 
contrast to the 5-to 15-fold changes observed at the injected disease site (Fig. 5) . Small changes in [ 18 F]FHBG uptake at untreated tumor sites after CTL infusions versus baseline scans were confirmed in an additional patient (patient 4). In this patient, [ 18 F]FHBG total activity in the CTL-treated focus was increased 2.2-fold on the post-CTL scan, increasing from 2.9 at baseline to 6.3 at the site of tumor recurrence, whereas the focus corresponding to the primary untreated site increased just 32%, from 2.4 to 3.2 ( fig. S10) The CTL infusion techniques used in this study are also expected to play a role in the survival of CTLs in vivo and their homing to the tumor site. In patient 3 (NCT01082926), the CTLs were injected using a slow infusion technique over several hours. This delivery technique resulted in cell clumping that may have reduced cell viability; however, [ S10, A and B) . These findings suggest that the dilution phenomenon might potentially affect the therapeutic effect by reducing the overall number of CTLs at the recurrent tumor site. On the other hand, this might be beneficial for patients whose tumors are located next to the ventricular system and are at a higher risk of spinal leptomeningeal dissemination (30, 31) . Nevertheless, these explanations require further validation.
The tumor vascular supply may also affect the ability to track CARengineered CTLs with [ 18 F]FHBG. In patient 5, the recurrent glioma was adherent to the dura mater, which contributed to a rich vascular supply with disrupted blood-tumor barrier. As a consequence, intravenously 
DISCUSSION
Malignant gliomas are the most frequently occurring primary brain tumors and are associated with a very poor survival rate (32) . Tremendous efforts have focused on the design of diagnostic and therapeutic tools for this devastating disease, among which targeted immunotherapy holds great promise (33) . Unlike current conventional cancer treatments, the potential of immunotherapy resides in selectively targeting cancer cells while leaving healthy cells unharmed. One of the main immunotherapeutic methods under exploration is through CAR engineering of CTLs to become tumor-reactive and tumor-specific (34) .
To fully validate immunotherapeutic strategies, it is crucial to monitor the viability, biodistribution, and trafficking of therapeutic cells to the site of the tumor. At present, there is no means to assess the fate of these cells. Imaging via MR, optical, or nuclear medicine-based techniques, however, has the potential to noninvasively monitor and track these cells in vivo. Two main approaches have been undertaken for cell tracking: direct and indirect labeling methods (35, 36) . Direct labeling of cells involves incubation and retention of an imaging agent by the therapeutic cells that are injected into the subject, with the imaging agent monitored over a time course of hours to days. One example of a direct labeling method, using superparamagnetic iron oxide-labeled cells, has demonstrated great potential for the accurate assessment of imageguided cell injection into the tissue of interest (37) .
Although they are relatively inexpensive and easy to perform, direct labeling methods are hampered by potential toxicity to the therapeutic cells (38) . Moreover, the contrast agent becomes diluted upon cell division and is lost from the cells upon cell death, making image analysis difficult to interpret (39) . To circumvent these issues, we and others (40) (41) (42) (43) have developed noninvasive indirect imaging reporter strategies to successfully track these cells. These methods enable imaging over the entire lifetime of the cell, with signal maintained after cell division, and provide information regarding cell viability (39) . Most of the signal is obtained from living cells because the production of the imaging reporter is dependent on the translation of a gene into a functional protein, in a process requiring adenosine 5′-triphosphate. Here, we demonstrated in humans that therapeutic CAR T cells can be detected noninvasively after intracranial adoptive transfer, through the PET imaging of a reporter gene.
CTLs were engineered to express the tumor-targeting IL-13 zetakine CAR and the wild-type HSV1-tk reporter gene, with HSV1-TK expression monitored by [ F]FHBG incubation also had no effect on CTL proliferation rate in cell culture, presumably because of the low amount of mass tracer used. The functional and cytolytic activity of CTLs obtained from patient 1 has been shown previously (18) . For all other patients, insufficient tumor material was obtained at biopsy to enable primary glioblastoma or patient-derived xenografts to be established in immunocompromised mice. Therefore, we could not assess functional activity of the CTLs against each patient's glioblastoma cells.
[ Because the location of the CTLs within the brain cavity was unknown, better imaging metrics were needed to replace single-voxel measurements, such as SUV max , to define both the location and quantity of the therapeutic cells. We used a contouring algorithm based on a set radioactivity threshold value relative to SUV max to determine an accurate VOI. Using this method, we could accurately assess not only tumorassociated CTLs but also poorly targeted CTLs and CTLs that had targeted diffusely growing tumor cells undetected on contrast-enhanced MRI. For quantitation, we assessed [ In summary, this work highlights an approach that uses a specific PET tracer to image HSV1-tk reporter gene expression in engineered CTLs to monitor CAR therapy for the treatment of high-grade gliomas.
MATERIALS AND METHODS
Study design
The primary research objective was to test the feasibility of [ 18 F]FHBG gene reporter imaging for the monitoring of therapeutic T cell distribution and viability in glioma patients. Patients from 18 to 70 years old with an average clinical status (a Karnofsky performance status of >60) and evidence of disease progression 12 weeks after the end of radiotherapy were included in this study. Exclusion criteria were a survival expectation of less than 4 weeks; any organ dysfunction; a large tumor requiring decompression surgery; a tumor located in the basal ganglia, thalamus, or brainstem; a patient treated for severe infection or recovering from major surgery; a history of IL-2 intolerance; and a history of ganciclovir and/or MRI contrast allergy or intolerance. The authors were not blinded to the results, and no randomization was performed.
Patient recruitment
Seven patients (four men and three women; mean age ± SD, 57 ± 8 years old) were prospectively enrolled from April 2006 to October 2013 in two separate clinical trials to evaluate the safety and feasibility of intratumoral immunotherapy with CTLs (Table 1) . Patients 1 and 2 were treated with autologous CTLs (NCT00730613) (17) , whereas patients 3 to 7 received allogeneic CTLs (NCT01082926). Patients included in this study were diagnosed with recurrent glioblastoma overexpressing the IL-13Ra2 receptor, thus allowing the recognition of malignant glioma cells by the genetically modified CTLs (17, 19, 48) . It was previously shown that patient prognosis and survival are inversely proportional to the abundance of tumor-associated IL-13Ra2 (25) . Nevertheless, the presence of these specific targets helped to define patients who would likely benefit and respond to immunotherapy. No patient received additional radiotherapy or chemotherapy throughout this study. All patients were initially treated and followed up at the City of Hope, Duarte, CA. The IRB and the local ethics committee approved all study protocols, and informed consent was obtained from each patient.
CTL engineering
The T cell manufacturing process was described previously in detail (17) . For patients 1 and 2, T cells were expanded from clones that had been selected from genetically modified T cells isolated from the patient's peripheral blood mononuclear cells (PBMCs). A plasmid DNA construct encoding the IL-13 zetakine CAR and the wild-type HSV1-tk genes under the transcriptional control of a modified human elongation factor-1a promoter and the cytomegalovirus immediate/ early promoter was transfected into the isolated cells using electroporation in a cell production facility at the City of Hope, Duarte, CA. Hygromycinresistant CTLs were cloned in limiting dilution, then expanded using the rapid expansion method (REM) to numbers in excess of 10 9 , and subsequently cryopreserved (17) . After the diagnosis of tumor relapse, the cryopreserved cells were thawed, REM-expanded, and formulated for intracranial infusion in 2 ml of preservative-free normal saline (PFNS). For patients 3 to 7, the GRm13Z40-2 CTL line was derived from a healthy volunteer donor apheresis unit. The GRm13Z40-2 CTL line is an ex vivo expanded allogeneic genetically modified oligoclonal CD8 + CTL line that expresses the IL-13 zetakine CAR and contains a biallelic deletion in the GR to confer steroid resistance. PBMCs were subjected to electroporation to introduce plasmid IL-13 zetakine CAR DNA, followed by activation with monoclonal antibody muromonab CD3 (30 ng/ml; trade name Orthoclone OKT3, marketed by JanssenCilag), ex vivo REM expansion (17) , and selection in the presence of cytotoxic concentrations of hygromycin (0.2 mg/ml). Hygromycinselected IL-13 zetakine CTLs were then subjected to transfection using the chimeric Ad5/35 adenovirus encoding a zinc finger nuclease (ZFN) pair that targets the human GR, which caused permanent disruption of the reading frame. Adenovirus-transfected IL-13 zetakine CTLs were subjected to selection in dexamethasone. Surviving T cells underwent large-scale REM expansion followed by cryopreservation to generate an allogeneic IL-13 zetakine CTL bank. After the diagnosis of recurrent glioblastoma, the cryopreserved cells were thawed and formulated for intracranial infusion in 2 ml of PFNS.
Infusion methods
Patients 1 and 2 underwent craniotomy for tumor resection and placement of Rickham reservoir and catheter for CTL injection, as previously detailed (17) . These patients were treated with a series of 12 infusions of autologous CTLs (each for 10 min) on days 1, 3, and 5 over a period of 5 weeks, with a break on week 3. If the initial dose of 1 × 10 7 CTLs was tolerated, subsequent infusions were increased to 5 × 10 7 and then 1 × 10 8 autologous CTLs per injection. Patients 3 to 7 had unresectable recurrent glioblastoma. These patients underwent stereotactic tumor biopsy and insertion of Rickham reservoir/catheter for intratumoral CTL infusion. These patients were treated with a series of four infusions of 1 × 10 8 allogeneic CTLs along with escalating doses of recombinant human IL-2 to prolong the survival of CTLs (49) . Allogeneic CTLs were infused on days 1 and 3 for two consecutive weeks; IL-2 was infused on days 2, 3, 4, and 5 of the first week (2500 IU/day) and on days 1, 2, 3, 4, and 5 of the second week (5000 IU/day) (table S3). In patient 3, CTLs and IL-2 were administered directly into the tumor cavity by convectionenhanced delivery, which is a drug delivery strategy designed to circumvent
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the central nervous system defense system and improve drug distribution (50) . It allows for delivery of high concentrations of therapeutic agents directly into brain tumors and surrounding parenchyma with minimal systemic toxicity. Because of cell clumping associated with slow infusion, the CTL delivery technique was switched to a "manual push" technique for 10 min in patients 4 to 7.
Clinical assessment
Before each [ 18 F]FHBG scan, we obtained a physical exam, a 12-lead electrocardiogram (ECG), vital signs (blood pressure, heart rate, respiratory rate, body temperature, and blood oxygenation), blood sampling (for complete blood chemistries, complete metabolic panel, international normalized ratio, and activated partial thromboplastin time), and urine (for urine analysis and pregnancy test, if needed). These values were used as a baseline. The patients' routine medications and medical history were also recorded. Vital signs were taken at 5, 10, 15, 60, and 120 min after [ 18 F]FHBG injection. ECGs were monitored every 15 min up to 120 min after the tracer injection and were analyzed for PQ/QRS and QT changes.
After the PET scan was completed, another set of vital signs and ECG were collected. Within 24 hours of the scan, the participants returned to the clinic, and vital signs and ECG were again collected, as well as blood and urine samples. Seven days later, a similar assessment was performed in addition to a neuropsychological test (mini mental state examination) that was also performed at baseline. Any adverse events noted by the members of the research team or the participants during the whole procedure were recorded for up to a week during follow-up.
Imaging studies [ 18 F]FHBG was synthesized as previously described (22) . The mean [ 18 F]FHBG activity injected was 259 ± 7 MBq (7.0 ± 0.2 mCi), with no significant differences between pre-and post-CTL infusion PET scans (P > 0.05). The maximum amount of unlabeled product was less than 2 mg, and the specific activity was greater than 37 Gbq/mmol (22) .
The tracer was administered as a bolus injection for less than 5 s via a hand or an arm vein. About 2 hours after intravenous injection of [ 18 F]FHBG, PET images were obtained from the skull vertex to the midthighs. Scans for patients 1 and 2 were performed with a standalone PET scanner (Siemens ECAT EXACT HR+ PET scanner, CTI PET Systems Inc.). [ 18 F]FHBG PET scans, at 7 min per bed position, were performed for both patients 1 and 2, but no baseline scan was done for patient 1 (16) . In addition, delayed brain PET images were obtained for patient 1. After the emission scan, the patient underwent a transmission scan for 3 min per bed position, using three rotating 68 Ge rod sources. PET images were reconstructed with the ordered subset expectation maximization algorithm with attenuation correction on a 128 × 128 matrix size. The images for patients 3 to 5 were obtained with a PET/ computed tomography (CT) scanner (Siemens Biograph TruePoint 64-slice). A topogram scan [120 kilovolt peak (kVp); 35 mA⋅s] was acquired, followed by a low-dose noncontrast CT (helical mode; rotation, 0.5 s, slice thickness, 5.0 mm; 120 kVp; 100 mA) for attenuation correction and anatomic localization. PET images were obtained in 3D mode for 7 min per bed position, using an iterative reconstruction algorithm (two iterations and 24 subsets) on a 168 × 168 matrix size and a Gaussian filter cutoff of 5.0 mm. Images for patients 6 and 7 were obtained on another PET/CT scanner (Siemens Biograph mCT 64-slice). All image protocols were similar to those on the Biograph TruePoint, except for the matrix size, which was larger at 200 × 200. All PET images were decay-corrected to the time of injection. Each patient was asked to void their bladder before each scan to reduce their total radiation exposure. ]FHBG images were analyzed in all axial planes and with different thresholds to detect subtle abnormal uptake. SUVs were measured in different areas using a 3D 50-mm-diameter spherical VOI for healthy tissue. Values were obtained for the left ventricle of the heart (referred to as blood pool); the left and right lung parenchyma; the right hepatic dome (referred to as liver); the left and right quadriceps musculature (referred to as thigh); the bone marrow; the left and right frontal lobes, parietal lobes, temporal lobes, and occipital lobes; and the cerebellum (table S2) . Activity within all brain areas except the site of surgical resection or tumor recurrence was averaged to represent the background brain uptake. An irregular 3D VOI was drawn over the abnormal uptake area in the brain (tumor recurrence and/or CTL foci). We used the native volume growth algorithm from MIM Encore version 6.4 (MIM Software) and applied different thresholds for delineation. A 10% threshold of SUV max was initially drawn, and 10% increments were subsequently applied until 90% of SUV max was obtained. MR and [ ]FHBG PET images were fused together to optimally visualize the uptake area. To do this, rigid body registration with rotations was initially applied, followed by deformable registration. In most cases, the delineation on [ 18 F]FHBG PET images followed the enhancing boundaries visualized on T 1 postgadolinium sequence on MR images. For treatment response, we always considered the background activity as part of baseline normal brain uptake. Therefore, we subtracted background activity from the activity measured in each VOI.
Different strategies were used for evaluating therapy response. We used SUV max , SUV mean , 3D volumes encompassing the tumor, individual voxel histogram analysis, and a parameter that takes into consideration the [ 18 F]FHBG concentration and the VOI. This parameter, referred to as total activity, corresponds to the SUV mean multiplied by the VOI. To calculate the percentage of signal change between two scans, we used a formula that accounted for the background activity in the brain:
ðPost-CTL SUV lesion À SUV backgroundÞ À ðPre-CTL SUV lesion À SUV backgroundÞ Pre-CTL SUV lesion À SUV background
Â100
Movie rendering was performed with Amira version 5.2.2 (Visage Imaging Inc.).
Assessment of [ 18 F]FHBG toxicity to transduced CTLs
The patient-derived CTLs GRm13Z40 (HD040-IL13z-ZFN) (control cell ID #cJ05105) and WCB-031-4C11-01 [UPN-031-IL13-zeta_DIIHyTK-pMG (pj00429#7)Cl.4C11] (cell ID #cj02331) were obtained from the T cell therapeutics laboratory at the City of Hope, Duarte, CA, as frozen vials. The CTLs were recovered in RPMI (Roswell Park Memorial Institute) medium with L-glutamine and Hepes. Human IL-2 (50 U/ml) was added as a supplement. Cells (15,000) for each cell type were plated in a 96-well tissue culture dish in RPMI medium. For the cells that needed to be exposed to the tracer, 7.4 kBq of [ 18 F]FHBG was added to each well. One hour after exposure to the tracer, cells were washed with phosphate-buffered saline twice and either lysed for counting accumulated radioactivity or plated in medium for an additional 24 and 48 hours. Viability assessment was performed using the Presto Blue assay as per the manufacturer's instructions (Thermo Fisher). Presto Blue uses the reducing environment of living cells to quantify viability. In brief, the desired volume of Presto Blue was added to the cells to a final concentration of 10%. The accumulated fluorescence was quantified using a microplate reader (excitation, 540 nm; emission, 600 nm) 30 min and 1 hour after the addition of Presto Blue. Table S1 . Patient survival data after diagnosis and initial CTL infusion. 
Statistical analysis
